Greenphire says patient enrollment for global clinical trials has returned to pre-COVID levels. New data from Greenphire indicates that new patient enrollment in trials that it provides services for globally has rebounded—up 85% since the trough in April. This data comes off the heels of a survey conducted over the summer, in which 71% of the 150+ sponsors and CROs that answered said the pandemic forced them to pause existing study enrollments and 58% had delayed existing study starts.
"The industry was hit hard by COVID-19 and at one point, nearly all research came to a stop. It's impressive to see the rebound in patient enrollment and the industry's ability to respond so quickly, in part by leveraging new technologies which promote flexibility of how visits are conducted. We anticipate this trend will continue as 84% of our survey respondents said they are actively seeking to increase their use of tools to better support decentralized trials," said Jim Murphy, Chief Executive Officer at Greenphire.
Find more of the survey’s data, here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.